Anixa Biosciences Inc (ANIX)
3.00
+0.13
(+4.53%)
USD |
NASDAQ |
May 10, 16:00
3.005
0.00 (0.00%)
After-Hours: 20:00
Anixa Biosciences Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| April 30, 2023 | 23.33% |
| January 31, 2023 | |
| October 31, 2022 | |
| July 31, 2022 | |
| April 30, 2022 | |
| January 31, 2022 | |
| October 31, 2021 | |
| July 31, 2021 | |
| April 30, 2021 | |
| January 31, 2021 | 24.95% |
| October 31, 2020 | |
| July 31, 2020 | |
| April 30, 2020 | |
| January 31, 2020 | |
| October 31, 2019 | |
| July 31, 2019 | |
| April 30, 2019 | 33.50% |
| January 31, 2019 | |
| October 31, 2018 | |
| July 31, 2018 | 33.47% |
| April 30, 2018 | 33.24% |
| January 31, 2018 | |
| October 31, 2017 | |
| July 31, 2017 | 61.07% |
| April 30, 2017 |
| Date | Value |
|---|---|
| January 31, 2017 | |
| October 31, 2016 | 64.01% |
| July 31, 2016 | 29.73% |
| April 30, 2016 | |
| January 31, 2016 | |
| October 31, 2015 | |
| July 31, 2015 | 14.15% |
| April 30, 2015 | -382.5% |
| January 31, 2015 | 62.52% |
| October 31, 2014 | 8.62% |
| July 31, 2014 | 86.31% |
| April 30, 2014 | 51.50% |
| January 31, 2014 | |
| October 31, 2013 | 24.21% |
| July 31, 2013 | |
| April 30, 2013 | |
| January 31, 2013 | |
| October 31, 2012 | 71.03% |
| July 31, 2012 | 99.71% |
| April 30, 2012 | 99.80% |
| January 31, 2012 | 99.84% |
| October 31, 2011 | 99.87% |
| July 31, 2011 | 99.19% |
| April 30, 2011 | 71.64% |
| January 31, 2011 | 69.30% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
23.33%
Minimum
Apr 2023
24.95%
Maximum
Jan 2021
24.14%
Average
24.14%
Median
Gross Profit Margin (Quarterly) Benchmarks
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 81.54% |
| IGC Pharma Inc | 65.20% |
| NovaBay Pharmaceuticals Inc | 48.70% |
| Protalix BioTherapeutics Inc | 15.54% |